Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

[News]

Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in gastrointestinal stromal tumors (GIST) and a Phase 1 trial of ganetespib in solid tumors evaluating a twice-weekly administration schedule.

More... (http://www.news-medical.net/news/20110607/Synta-presents-ganetespib-Phase-1-2-trial-results-against-solid-tumors-at-ASCO-2011.aspx)